Streptococcus pneumoniae conserved surface protein (Pneumococcal surface protein)

Streptococcus pneumoniae conserved surface proteins represent a diverse group of antigens found across nearly all pneumococcal serotypes, making them ideal targets for broad-spectrum vaccine development. Unlike traditional polysaccharide vaccines that are limited by serotype specificity, these proteins—including Pneumococcal surface protein A (PspA), Pneumococcal surface protein C (PspC), and Pneumococcal surface adhesin A (PsaA)—play critical roles in the pathogen's ability to colonize the nasopharynx, evade the host immune system, and cause invasive disease (Cunningham et al., 2021, PubMed). For instance, PspA inhibits complement-mediated opsonization, while PsaA acts as a manganese transporter essential for bacterial growth and adhesion (Rajam et al., 2008, Critical Reviews in Microbiology). Therapeutic strategies targeting these proteins primarily focus on protein-based vaccines designed to elicit protective antibody responses that facilitate bacterial clearance via opsonophagocytosis. Several candidates, such as GEN-004 (containing PhtD and StkP), have been investigated in clinical trials to provide coverage against the 100+ known serotypes of S. pneumoniae (Genocea Biosciences, 2015). By targeting conserved structural elements, these therapies aim to overcome the limitations of current conjugate vaccines, such as serotype replacement and high manufacturing complexity, while providing a more robust defense against pneumonia, meningitis, and febrile bacteremia (Lagousi et al., 2019, Vaccine).

Other names

Conserved pneumococcal antigensPneumococcal surface proteinsPneumococcal virulence factorsPspAPspCPsaAPhtD

Induction of opsonophagocytic antibodies, neutralization of virulence factors, and inhibition of bacterial colonization and adherence to host tissues.